用伊马替尼布治疗的PDGFRA重组驱动的专属肺部参与的克隆性埃索因菲利亚:一个病例报告
Zaineb Mlayah1, Inés Ben-Rekaya1, Inaam Bizid1
1Clinical hematology department of Fattouma Bourguiba Hospital, Monatir, Tunisia.
Leukemia research reports
|March 21, 2025
概括
本病例报告详细介绍了一种罕见的克隆性过敏氨酸性综合征 (HES) 病例,它只影响肺部. 用伊马替尼布治疗显示,在降低乙氨基酸细胞数量方面,初始反应是积极的.
科学领域:
- 血液学 血液学 血液学
- 肺部病理学 肺部病理学
- 罕见疾病 罕见疾病
背景情况:
- 过敏氨酸性综合征 (HES) 是一种罕见的多系统性疾病,具有显著的发病率和死亡率.
- 与FIP1L1-PDGFRA重组相关的克隆HES异常罕见,特别是在孤立的肺部参与的情况下.
相关概念视频
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K